Lilly Signs $1.9B Kidney Gene Therapy Deal as Analysts Forecast 25% Earnings Growth
LLY•Lilly agrees a deal worth up to $1.9B with Ascidian Therapeutics for RNA exon-editing kidney disease treatments, adding to its $1.1B Seamless and $1.3B Verve agreements. Analysts forecast 25% annual earnings growth on obesity drug momentum from Foundayo and predict Lilly’s market cap will exceed $1.8T SpaceX within two years.
1. Deal Terms and Scope
Lilly secured exclusive rights to Ascidian’s RNA exon-editing platform for certain kidney disease targets under a deal worth up to $1.9 billion. This agreement follows a $1.1 billion pact with Seamless Therapeutics for hearing loss and a $1.3 billion acquisition of Verve Therapeutics in 2025, expanding Lilly’s genetic medicine pipeline.
2. Research and Commercialization Roles
Ascidian will lead early-stage research and preclinical work on the kidney disease programs, while Lilly will assume responsibility for late-stage clinical development, manufacturing, and commercialization. Ascidian stands to receive an upfront payment, multiple development and sales milestones, and royalties on any future products.
3. Earnings Growth and Valuation Outlook
Analysts are pricing in 25% annual earnings growth fueled by momentum from Lilly’s obesity drugs, including the recently launched Foundayo and upcoming pipeline candidates. One projection suggests Lilly’s market capitalization could surpass SpaceX’s $1.8 trillion valuation within two years, underscoring bullish investor sentiment.
